Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.44 |
| ▸ | MET | P08581 | 9/20 | 0.44 |
| ▸ | FLT1 | P17948 | 6/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306874 | 0.84 | KDR (0.49) | KDRMETFLT1GRIN3BGRIN1 | |
| SCHEMBL10272795 | 0.83 | KDR (0.47) | KDRMETFLT1 | |
| SCHEMBL306922 | 0.81 | KDR (0.46) | KDRMETFLT1 | |
| SCHEMBL14230733 | 0.77 | MET (0.70) | KDRMET | |
| SCHEMBL4603637 | 0.77 | KDR (0.49) | KDRMETFLT1 | |
| SCHEMBL896589 | 0.75 | MET (0.70) | KDRMET | |
| SCHEMBL307961 | 0.74 | MET (0.65) | KDRMET | |
| SCHEMBL307962 | 0.73 | MET (0.44) | KDRMETGRIN3BGRIN1GRIN2C | |
| SCHEMBL306971 | 0.72 | GRIN3B (0.43) | KDRFLT1GRIN3BGRIN1GRIN2C | |
| SCHEMBL308564 | 0.72 | KDR (0.46) | KDRMETFLT1GRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | KDR 4/4885MET 2/4885FLT1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.